

Annual Report



Instituto
de Salud
Carlos III

2024

Annual Report

2024

isc
Instituto
de Salud
Carlos III

Edit
Ministry of Science, Innovation and Universities



Editing and Layout
FECYT



Copyright/licence of use
Attribution — Non-commercial use Share equal
by-nc-sa

Commercial use of the original work and any derivative works is not permitted, and distribution of derivative works must be under a licence equal to that governing the original work.

General Catalogue of Official Publications

Publication included in the editorial
programme of the Ministry of
Science, Innovation and Universities



To all the people
who are part of
the Institute, for
their effort and
contribution to the
preparation of this
document, without
whom the ISCIII
would not be the
leading institution
that it is today

Contents

06



01
Presentation

14



02
Summary of ISCIII
Activities

20



03
Promoting,
Coordinating and
Implementing
Health Research and
Innovation

36



04
Strategic Project:
PERTE for Cutting-
Edge Health

46



05
2024 Highlights



Presentation

01

“ Once again this year, we are helping to generate scientific knowledge, with our own research work, science funding, consultancy and training, and the provision of scientific and technical services, as well as a firm commitment to the communication and dissemination of science and health.

Prof. Marina Pollán Santamaría
Director of the ISCIII



Presentation

The 2024 report of the Carlos III Health Institute (by its Spanish initials, ISCIII) reflects once again the activity carried out by our Institute as a public health research organisation at the service of the Spanish Science, Technology and Innovation System (by its Spanish initials, SECTI) and the National Health System (NHS). Personally, it is a special report, as it summarises our work in what was my first year as Director.

I would like to begin by recalling that, without all the people who are part of the Institute, to whom I am extremely grateful for their work and continuous dedication, the ISCIII would not be the benchmark organisation that it is. We are a bridge between Science and Health and we strive to make the former a guarantee for the latter.

The year 2024 was relevant for many reasons. This is the first full year without the shadow of a worldwide pandemic such as COVID-19, a disease that we continue to research and monitor at the Institute, and with which we have fortunately become accustomed to coexisting, reducing its impact. However, this positive news was overshadowed by the devastating effects of the DANA in the Valencian Community, a catastrophe that marked the end of 2024 and will go

down in history. Once again, let this report serve as a remembrance of and solidarity with the people who were affected by this tragedy. At the Institute, we try to do our bit by collaborating in the aid work as part of the health response group created by the Administrations, carrying out consultancy work in microbiological, epidemiological and environmental surveillance.

The year 2024 will also go down in history as the 100th anniversary of our National School of Health ('ENS' in Spanish), the oldest Spanish institution specialising in research and training in public health and health administration. I must point out that it is a real privilege to have the ENS in the ISCIII.

Another of the highlights of 2024 at the ISCIII was another celebration,

that of the 10th anniversary of the Centro de Investigación Biomédica en Red (CIBER) Consortium. The CIBER-ISCIII Consortium is a multidisciplinary, cooperative and networked biomedical research structure that brings together more than 6,000 researchers from multiple research centres and groups from different public and private administrations and institutions throughout Spain. These ten years have demonstrated that its model is a success for the Spanish biomedical science system.

I also don't want to fail to mention—because it is a fundamental project and because I have had the good fortune of being directly involved in its development—the hosting at ISCIII of the first international meeting on the IMPaCT Precision Medicine



Infrastructure. This is a national project promoted, funded, and coordinated by the Institute, which in 2024 marked its third year and aims to foster and consolidate personalised medicine within the scientific and healthcare systems, thanks to the work of its three coordinated pillars: Predictive Medicine, Data Science and Genomic Medicine.

I do not want to say much more in these introductory lines. I would just add that in 2024 we also hosted the launch of the Health and Climate Change Observatory, an interministerial initiative with scientific leadership headed by the ISCIII. It is also significant to note that the ISCIII Doping Control Laboratory's participation in clean sport control work at the Paris Olympic and

Paralympic Games took centre stage during the summer.

Throughout the year, we continue to strengthen our commitment to internationalisation and our participation in the European Research Area. And, in our work as a funding body, we earmarked almost 300 million to promote R&D&I in health in Spain (12% more than the previous year), within the framework of our Strategic Action in Health ('AES' in Spanish), the main tool for funding biomedical and health research in Spain.

In short, throughout the year 2024, we will once again be helping to generate scientific knowledge, with our own research work, science funding, consultancy and training, and the provision of scientific and technical services, to which we

add a firm commitment to the communication and dissemination of science and health.

All ISCIII employees should feel proud that the science we carry out in our Institute, thanks to the activity of our own research centres and units, continues to allow very important advances in the fight against disease and in health care. This has been the case since our foundation in 1986, and will continue to be the case in the years to come.

Marina Pollán Santamaría
Director of the ISCIII


The year 2024 will also go down in history as the 100th anniversary of our National Health School (ENS), the oldest Spanish institution specialising in research and training in public health and health administration.

Summary of ISCI activities


02

ISCIII 2024 in numbers


ISCIII staff




Budget




FINANCING AND COORDINATION OF R&D&I IN THE NATIONAL HEALTH SYSTEM (NHS)



ESF FUNDS




PUBLICATIONS BY CENTRES AND UNITS



TOTAL ESA-2024 FUNDING IN PROGRAMMES AND SUB-PROGRAMMES COORDINATION OF R&D&I

State Programme for Developing, Attracting and Retaining Talent



State Training Sub-Programme



State Incorporation Sub-Programme




State Mobility Sub-Programme



State Programme for the Promotion of Scientific-Technical Research and its Transfer



State Knowledge Generation Sub-Programme



State Knowledge Transfer Sub-Programme




State Sub-Programme for Institutional Strengthening







State Programme to Address Environmental Priorities



State Sub-programme for Internationalisation



INTRAMURAL SCIENTIFIC ACTIVITY OF THE ISCIII



Training activities

VIRTUAL CAMPUS FOR HEALTH PROFESSIONALS

▶ **29,446**
of students in 30 training actions

NATIONAL HEALTH SCHOOL

▶ **732**
of students and 3,830 teaching hours taught

NATIONAL OCCUPATIONAL MEDICINE SCHOOL

▶ **339**
students

NATIONAL HEALTH SCIENCE LIBRARY

▶ **43,311**
publications
(Bibliographic holdings)

▶ **37,607**
database queries

▶ **+92**
million visits to SciELO Spain
(Spanish Health Science Journals in Open Access)

Scientific-Technical Support Services to the National Health System

▶ **3,500**
RBD (Receptor Binding Domain) determinations of SARS-CoV-2 and 3,500 determinations of SARS-CoV-2 nucleocapsid in **CNE Public Health Surveillance**

▶ **27**
Microbiological Surveillance programmes (bacteria, parasites, viruses and fungi)


▶ **110,281**
tests and reports on air pollution, calibration of ozone transfer standards, radiation protection and environmental toxicology

▶ **144**
characterised outbreaks (Botulism, Viral gastroenteritis, Legionellosis, Salmonellosis, Hepatitis A and Anthrax)

▶ **36,999**
diagnostic and/or referral determinations from the **CNM Service Portfolio**

▶ **63**
performances in the **genetic diagnosis** of Retinoblastoma, Alpha-1 Antitrypsin Deficiency, Diagnosis of Undiagnosed Patients and Epidermolysis Bullosa

▶ **3,198**
services provided by the **Doping Control Laboratory** in-competition and 2,489 out-of-competition services



Technology Transfer and Innovation

PROTECTION OF RESULTS

▶ **2**
No. of priority patent applications

▶ **97**
No. of active patents

TRANSFER OF RESULTS

▶ **25**
No. of legal transactions signed without economic content

▶ **3**
No. of legal transactions signed with economic content

Cutting Edge Health PERTE

€2,358.61 M
in investment

▶ **€2,056.89 M**
of public investment

▶ **€301.42 M**
of private investment

The ISCIII accounts for **22%** of the total public contribution to the PERTE for Cutting-Edge Health with the management of **€409.19 M** and a total execution of **89%**

ISCIII ACTIONS

▶ **€24.96 M**
Joint missions of the Ministry of Science, Innovation and Universities and the Ministry of Health for the implementation of Precision Medicine — Genomics. **For 7 research groups**

▶ **€18.80 M**
Call for Independent Clinical Research Projects. **For 19 research groups**

▶ **€67.50 M**
Advanced Therapies on the Majadahonda campus for a total value of **€67.50 M** and 85% completed

▶ **€27.99 M**
Clinical Research Units **Establishment Modality** for **12 research centres**

▶ **€19.92 M**
Joint missions of the Ministry of Science, Innovation and Universities and the Ministry of Health for Rare Diseases. **For 8 research groups**

▶ **€16.87 M**
Clinical Research Units **Improvement Modality** for **15 research centres**

▶ **€0.43 M**
Human biomonitoring infrastructure

▶ **€2.39 M**
Proteomics and metabolomics platform

Communication

▶ **+2.8 M**
visits to the ISCIII website

▶ **89**
press releases sent to the media

▶ **161**
information notes published on the website and 5 informative notes

X
+ 2.8% growth on the social network X compared to 2023

in
80% growth on LinkedIn compared to 2023. More than 1,150,000 impressions

▶
65.8 M views
60 videos published
34 live broadcasts
489.1 million impressions

Promoting,
Coordinating and
Implementing
Health Research
and Innovation

03





Promoting, Coordinating and Implementing Health Research and Innovation

The Sub-Directorate General for Evaluation and Promotion of Research (by its Spanish initials SGEFI) carries out the functions of the ISCIII in terms of planning, promotion and coordination of research and innovation in health through the management, concession and scientific monitoring during its execution of the actions associated with the Strategic Action in Health, as well as the evaluation and monitoring of Health Research Institutes (by its Spanish initials, IIS) through the Programme of Evaluation, Accreditation and Monitoring of IIS (by its Spanish initials, PEASIIIS).¹

ISO 9001:2015 QUALITY CERTIFICATION

The ISCIII has been certified by AENOR since 2021 for **UNE-EN ISO 9001:2015** (Certificate No. ER-0383/2021) for the scope "**Management of Strategic Action in Health (approval, publication and instruction of the call for proposals and scientific monitoring)**" and "**Management of the Evaluation, Accreditation and Monitoring of Health Research Institutes**".

¹Chapter 6

Strategic Action in Health

The Strategic Action in Health 2024 (hereinafter, AES 2024) is part of the State Plan for Scientific and Technical Research and Innovation for the period 2021-2023 (hereinafter PEICTI), an instrument designed to develop and finance the actions of the General State Administration in the field of R&D&I, to enable the achievement of the objectives and priorities included in the Spanish Strategy for Science, Technology and Innovation (hereinafter EECTI) for the period 2021-2027.

It also undertakes the planning, evaluation and selection of proposals in the actions of the Acción Estratégica en Salud Intramural (hereinafter AESI) that the ISCIII, in its capacity as executing agent, proposes to support the generation of knowledge within the framework of its centres and units.

By Resolution of the Directorate of the Instituto de Salud Carlos III O.A., M.P., of 20 December 2023, approving the call for applications for the year 2024, by means of advance processing, for the award of grants under the Strategic Action on Health 2021-2023, the actions were structured (Extract in BOE no. 305 of 22 December 2023, with identification code BDNS: 734336).

The funding of the call corresponded to the ISCIII budget, as established in Law 4/2023 of 29 December on General Budgets for 2024 (BOE no. 27 of 31 January 2024), and included funds from the "Mechanism for Recovery and Resilience" for the proper management of European funds from the agreement reached by the European Council on 21 July 2020 in the framework of the extraordinary Next Generation EU plan.

All AES 2024 actions are detailed below:

State Programme for Developing, Attracting and Retaining Talent

State Training Sub-programme (PGE)	▶ 293 No. of contracts	▶ €24,935,047 Funding
State Incorporation Sub-programme (PGE)	▶ 159 No. of contracts	▶ €24,935,047 Funding
State Mobility Sub-programme (PGE)	▶ 69 No. of contracts	▶ €24,935,047 Funding

State Programme for the Promotion of Scientific-Technical Research and its Transfer

State Knowledge Generation Sub-programme (PGE)	▶ 580 No. of contracts	▶ €24,935,047 Funding
State Knowledge Transfer Sub-programme (PGE, PRTR and PERTE)	▶ 246 No. of contracts	▶ €24,935,047 Funding
State Sub-Programme for Institutional Strengthening (PRTR and PERTE)	▶ 27 No. of contracts	▶ €24,935,047 Funding

State Programme to Address Environmental Priorities

State Sub-programme for Internationalisation (PGE)	▶ 293 No. of contracts	▶ €24,935,047 Funding
--	---------------------------	--------------------------


- ▶ 1,427
Aid granted in 2024
- ▶ €296,004,569.46
Funding

Funds: PGE, PRTR, PERTE

Success rate of AES 2024 actions



It should be noted that there has been a 13% increase in dedicated funding in 2024 compared to 2023, consolidating the trend started in 2019 as shown in the figure below.



Financing for Strategic Action in Health: developments in the period 2013–2024.



STATE PROGRAMME FOR DEVELOPING, ATTRACTING AND RETAINING TALENT

STATE TRAINING SUB-PROGRAMME (PGE FUNDING)

Pre-doctoral health research training contracts

Aimed at the initial training of research personnel in health sciences and technologies, through the completion of a doctoral thesis. There are two modalities, both with a maximum duration of 4 years, the duration of your stay in the doctoral programme.

» **A. PFIS contracts: pre-doctoral health research training contracts.** Aimed at research staff whose group leaders obtained a Health Research Project or International Collaboration Projects from the AES in the 2023 call.


» **B. i-PFIS contracts: IIS-industry doctorates in health sciences and technologies.** This action is aimed at promoting public-private collaboration through the development of part of the training programmes in the workplaces of accredited business entities and IIS.

Río Hortega (CM) Contracts

The aim of this action is the exclusive recruitment of professionals who have completed their Specialised Healthcare Training (FSE) in publicly-owned healthcare entities.

Sara Borrell (CD) Contracts

Aimed at research staff who have recently obtained their doctorate, with a duration of 3 years.



No. of applications accepted No. of applications funded Success rate

STATE INCORPORATION SUB-PROGRAMME
(PGE FUNDING)

Health Research Management Contracts (GIS) in the IIS

The purpose is to recruit staff to carry out R&D&I management support activities in the IIS for a duration of 3 years.




Miguel Servet (MS) Contracts

Aimed at research staff who have obtained a doctorate between 2012 and 2019 and have completed or are in the third year of a Sara Borrell Contract, or have completed or are in the second year of the Río Hortega programme and have obtained this degree, with a duration of five years. They are endowed with an additional grant of €40,000 for research expenses, and an additional grant of €66,100 to beneficiary R&D centres for the creation of permanent jobs.



Juan Rodés (JR) Contracts

For medical staff with experience in health sciences and technologies, in possession of the title of Specialist and the title of doctorate, who have completed or are carrying out a Río Hortega contract of the AES 2021 or 2022. They are carried out in public healthcare centres that are part of an accredited IIS. The contracted staff member shall be required to combine the care activity with the research activity.

They have an additional amount for those beneficiary centres that can demonstrate that they have created permanent clinical-research jobs.



No. of applications accepted No. of applications funded Success rate



No. of applications accepted Success rate
No. of applications funded

Contracts for the intensification of research activity in the SNS (INT)

Aimed at specialists or university graduates in Nursing, Dentistry or Physiotherapy who carry out 50% of the clinical-care activity of professionals in public centres at the same time as carrying out research activities. Grants, which may be for 1 or 2 years depending on the number of years of active project implementation remaining to be carried out to support the application.


Bioinformatics Technical Research Support Staff Contracts in the IIS (CA)

Earmarked for the recruitment of staff to carry out scientific/technical activities in the IIS for 2 years.

STATE MOBILITY SUB-PROGRAMME (PGE FUNDING)

Grants for the mobility of health professionals and researchers of the SNS (Modality M-BAE)


Aimed at financing stays of SNS health professionals and researchers in prestigious national or foreign institutions lasting between 60 and 365 days.



No. of applications accepted No. of applications funded Success rate

Grants for the mobility of research staff recruited under the AES (Modality M-AES)

Aimed at financing stays in foreign R&D centres or in Severo Ochoa Centres of Excellence and María de Maeztu Units of Excellence, for people with a PFIS, i-PFIS, Río Hortega, Sara Borrell, Juan Rodés or Miguel Servet contract, lasting between 60 and 365 days.




STATE PROGRAMME FOR THE PROMOTION OF SCIENTIFIC-TECHNICAL RESEARCH AND ITS TRANSFER


STATE KNOWLEDGE GENERATION SUB-PROGRAMME

Health R&D&I Projects (PI) (PGE funding)

Health R&D&I Projects (PI) represent the main source of support for research in the SNS and in the research centres linked to this field, with the aim of financing stable lines of research. Its duration is 3 years.



Health research projects funded under the Strategic Action on Health 2024: distribution by thematic area



STATE KNOWLEDGE TRANSFER SUB-PROGRAMME

Health Technology Development Projects (DTS) (PGE funding)

The Health Technology Development Projects (DTS) are applied projects aimed at promoting innovation in SNS healthcare centres and the transfer of innovative solutions, while at the same time allowing for the establishment of alliances between research entities and companies in the pharmaceutical, biotechnology and medical and healthcare technology sectors. Two modalities:

» **A. Proof of Concept (PoC) projects** validation of proposals to reach Technology Readiness Level (TRL) 3 or TRL 4, with a duration of 2 years.

» **B. Prototype Technology Validation Projects (PTV)** for projects aimed at achieving TRL 5 or 6, with a duration of 3 years.

Independent Clinical Investigation (ICI) projects (PGE funding)

The aim of this action is to promote academic research in trials with medicinal products for human use and/or advanced therapies (gene therapy, cell therapy or tissue engineering) that allow tangible advances to be achieved for patients and that provide evidence to the health authorities for their implementation in the SNS. The duration of each project is 4 years.

Incorporation of new groups into the CIBER Consortium (PGE funding)




Aimed at strengthening the CIBER Consortium by incorporating new groups into its subject areas.


Distribution of applications by subject area:

SUBJECT AREA	ACCEPTED APPLICATIONS	CONCESSIONS	SUCCESS RATE (%)
Neurodegenerative diseases	11	3	27.27%
Cancer	12	2	16.67%
TOTAL	23	5	21.74%

Success rate: ratio between successful and funded applications expressed in %.


● No. of applications accepted ▶ Success rate
● No. of applications funded






Personalised Precision Medicine Projects (PMP) (PRTR and PGE funding)

The purpose of this action is to promote the implementation of Personalised Precision Medicine through scientific research, by financing projects that make possible the development and implementation in the SNS of clinical and healthcare actions that, under the global concept of Personalised Precision Medicine, and in coordination with the IMPaCT infrastructure, make it possible to improve the prevention, diagnosis, treatment and/or quality of life of the population.



Rare Disease Research Projects (PMPER) (PRTR and PGE funding)

Action for research into rare and neuromuscular diseases with special emphasis on Amyotrophic Lateral Sclerosis (hereinafter ALS), by funding projects of proven quality aimed at resolving unmet needs identified through very close collaboration with sick people and their families, the validation in daily clinical practice of technologies, biomarkers and procedures of Personalised Precision Medicine, as well as those aimed at the design of this type of mechanism and its subsequent validation in the field of care.



Health Outcome-Oriented Cooperative Research Networks (RICORS) (PGE funding)

The purpose of this action is the creation and configuration of Health Outcomes-Oriented Cooperative Research Networks (RICORS) with the aim of promoting research oriented towards health outcomes by coordinating the research ecosystem in the SNS around a specific and defined research objective of specific use to the public as a whole. Progress is thus being made in the structuring of R&D&I between research groups from different Autonomous Communities, directing their research activity towards common objectives that enable results to be obtained that can be transferred to the population. Seven RICORS were funded for a total amount of €33,255,499.

Detailed information on successful and funded applications by gender, success rate and RICORS funding by **subject area** is detailed in the table below:

SUBJECT AREA	NAME RICORS	ACCEPTED APPLICATIONS			FINANCED			AMOUNT	SUCCESS RATE (%)
		M	H	TOTAL	M	H	TOTAL		
Inflammation and immunopathology of organs and systems	Inflammatory Diseases Network (IDN)	18	17	35	18	15	33	€4,872,074.68	94.29%
	RICORS2040-Renal	12	17	29	12	17	29	€3,968,074.00	100.00%
Primary care, chronicity and health promotion	Research Network on Primary Care in Addictions (RIAPAd)	8	14	22	6	13	19	€2,625,700.00	86.36%
	Research Network on Chronicity, Primary Care and Health Prevention and Promotion (RICAPPS)	13	12	25	12	9	21	€6,144,380.00	84.00%
	Spanish network in maternal, neonatal, child and developmental health research (RICORS- SAMID)	11	11	22	11	10	21	€3,207,710.00	95.45%
Advanced therapies	TERAV+	13	20	33	12	18	30	€7,098,798.27	90.91%
Cerebral vascular diseases	RICORS-ICTUS	11	17	28	11	15	26	€5,338,762.00	92.86%
Total		86	108	194	82	97	179	€33,255,498.95	92.27%



STATE SUB-PROGRAMME FOR INSTITUTIONAL STRENGTHENING


Improved Clinical Research Units (UICs) (PRTR and PGE funding)

This action is aimed at generating or improving clinical research ecosystems, paying special attention to those territories with a dispersed population and limited access to clinical research, thus aligning itself with the general objective of the Cutting-Edge Health PERTE, which focuses on improving the prevention, diagnosis, treatment and rehabilitation of patients in the National Health System. The aim is to provide Clinical Research Units (UICs) to ensure

equitable access to clinical research for people regardless of their place of residence, age and gender, and to foster the cohesive development of a clinical research pole of attraction.

Application modalities:

- » a) **Modality of Creation of a new Clinical Research Unit**, aimed at those centres that lacked a structured UIC.
- » b) **Improvement of a Clinical Research Unit modality** for those centres that had an operational UIC.



● No. of applications accepted ● No. of applications funded ► Success rate


STATE PROGRAMME TO ADDRESS ENVIRONMENTAL PRIORITIES

STATE SUB-PROGRAMME FOR INTERNATIONALISATION

International Collaboration Projects (PRTR and PGE funding)

The purpose of this action is to promote the internationalisation of the R&D&I of the SNS and SECTI agents by financing, through direct grants, the participation of Spanish entities in international consortium research projects that have successfully competed in joint European competitive calls for proposals under multilateral research and innovation programme agreements. The ISCIII participates as the funding body for the Spanish party, provided it has been selected for funding by the decision-making body of the corresponding European program.

In 2024, funding was granted to the 53 proposals that received a favourable evaluation from the decision-making body of the respective European program, with a total allocation of €9,307,729.25 and an execution period of 3 years.



Strategic Project: PERTE for Cutting-Edge Health


04



Strategic Project: PERTE for Cutting- Edge Health

The Economic Recovery and Transformation (PERTE) for Cutting-Edge Health Strategic Project is conceived as a nationwide initiative of general interest, both for the economy—due to its driving force and transformative potential—and for society, by promoting quality employment and improving the health of the Spanish population through scientific knowledge, cutting-edge healthcare innovation, and data as drivers of transformation.

The Cutting-edge Health PERTE started in November 2021 with a public-private investment of more than €1,469.32 million to be completed during the period 2021-2023. This budget has been increased to €2,358.61 million, with the incorporation of more actions (€396.45 million in public contributions) and with the signature in October 2023 of the Addendum-Second Phase of the MRR funds (€830 million in public contributions).



Consequently, the number of actions foreseen in the PERTE has increased both in number, from the initial 39 to the current 60, and in duration, extending until the last quarter of 2026.


The Cutting-Edge Health PERTE has an Inter-ministerial Governance made up of representatives of the participating Ministerial Departments, a Vanguard Health Alliance that guarantees a permanent dialogue between the public-private actors involved and, as of December 2023, its own

Commissioner for the coordination of monitoring, dialogue and visibility measures.


It is worth highlighting the leading role played by the ISCIII from the beginning, not only for the management of public funds (€460.34 M representing 22% of the public contribution to the PERTE) but also for having managed the PERTE Technical Office from its creation until the end of 2023, in charge of coordinating the information of all the ministerial departments involved in the PERTE.

ISCIII in the Cutting-Edge Health PERTE

The participation of the ISCIII has also evolved throughout the life of PERTE, both in terms of the volume of the budget to be managed and the number of actions to be carried out.



During the period 2021-2023, the ISCIII managed a total of 19 actions with an execution of almost €300 million, mostly charged to the European Funds of the Recovery, Transformation and Resilience Plan, but also to its own funds from the General State Budget.



The European Commission's approval of the Spanish Addendum to the PRTR led to the granting of an additional €830 million to the Cutting-Edge Health PERTE for new actions for both the ISCIII and the CDTI.

Within these new actions, the ISCIII is developing 7 new actions with an associated budget of €122 M, which brings the ISCIII's contribution to the Cutting-Edge Health PERTE to more than €460 M between grants and loans.

ISCIII develops

7 new actions

122 M in associated budget

+460 M between grants and loans

OE/LT	NEW ACTIONS ADDENDUM	€M
OE1	Joint Missions of the Ministry of Science, Innovation and Universities and the Ministry of Health for Rare Diseases	20
	Joint Missions of the Ministry of Science, Innovation and Universities and the Ministry of Health for the implementation of precision medicine - Genomics	25
LT1	Actions related to the development and strengthening of the capacity of the SNS for clinical research — Clinical Research Units	45
	Proteomics and metabolomics platform	2.4
	Human Biomonitoring Infrastructure	1
	Module for the generation of polytransgenic animals for xenotransplantation research	1.60
LT2	Financial support in the form of loans to SNS research centres for the expansion of their research and technological development capacities	27

The new economic resources of the PERTE for Cutting-Edge Health have made it possible during 2024 to boost investments aimed both at incorporating new technologies and equipment and at reinforcing the research and technological development capacities of the SNS, strengthening the Spanish R&D&I ecosystem at both the public and private levels.



Thus, the ISCIII ended the year 2024 with an execution of 89% with €409.10 million over its total activity, and 99% execution over the 2024 budget of €146.42 million, in the actions listed below:

OE 1. PERSONALISED AND PRECISION MEDICINE

Joint missions of the Ministry of Science, Innovation and Universities and the Ministry of Health for the implementation of Precision Medicine — Genomics ► €24.96 M for 7 research groups	Joint missions of the Ministry of Science, Innovation and Universities and the Ministry of Health for rare diseases ► €19.92 M for 8 research groups
---	---

OE 2. ADVANCED THERAPIES AND OTHER INNOVATIVE PHARMACEUTICALS

Call for Independent Clinical Investigation (ICI)

► **€18.80 M**
for **19** research groups

Advanced Therapies on the Majadahonda Campus

► €15 M BUDGET	► €6.24 M SPENT mainly on the construction of the building. 2022-2023	► 4 TENDERS	► €799,604.61 VALUE OF TENDERS for the purchase of office and laboratory furniture
The CTA will be one of the ISCIII's contributions to the State Network Consortium for the Development of Advanced Therapy Medicines (CERTERA), approved by the PRTR Commission during 2024	► 43 ENTITIES as nodes of the consortium	► €67.52 M TOTAL BUDGET of the Creation of the Consortium for Advanced Therapies CTA ¹	► 85% IMPLEMENTATION IN 2024

1. It includes the RICORS call belonging to the AES 2021 of the Advanced Therapies Network-TERAV, the Centre for Advanced Therapies and the call for incorporation into the State Network Consortium for the Development of Advanced Therapy Medicines (CERTERA).



LT1. DEVELOPING AND STRENGTHENING THE CAPACITY OF THE SNS FOR CLINICAL RESEARCH

- » Clinical Research Units:
 - Creation Modality: €27.99 M for 12 research centres
 - Improvement Modality: €16.87 M for 15 research centres
- » Proteomics and metabolomics platform. €2.39 M
- » Human biomonitoring infrastructure. €0.43 M

LT3. COLLABORATION AND COORDINATION BETWEEN SCIENCE AND INDUSTRY

- » ISCIII Clinical Research Platform — SCREN*
 - » Platform for the dynamisation and innovation of the industrial capacities of the SNS and their effective transfer to the productive sector ISCIII-ITEMAS**2
- Two actions are being pursued within the framework of this platform:
- » Portfolio of health innovation projects
 - » Monitoring system for projects in pre-clinical phases

OTHER ACTIVITIES 2024

- » Holding of the 4th PERTE Vanguard Health Alliance Meeting
- » Interim Evaluation Indicators Working Group Meetings
- » Vanguard Health Alliance Training Commission Meeting

INFORMATION ABOUT PERTE FOR VANGUARD HEALTH AT:



2. Both platforms are agglutinated in two cross-cutting lines LT1 and LT3

2024 Highlights

05


Instituto
de Salud
Carlos III


Instituto
de Salud
Carlos III

Instituto de Salud Carlos III


Instituto de Salud Carlos III

2024 Highlights

January

01/30

World Neglected Tropical Diseases Day 2024.
Possibilities of AI

<https://www.youtube.com/watch?v=xGf7rIPR41Q&t=55s>



February

02/08

VII International Day of Women and Girls in Science: "Science in society, science in the family"

<https://www.youtube.com/watch?v=A4GvRQ3Zomw&t=4044s>

02/21

Inauguration ceremony of the Director of the Carlos III Health Institute

<https://www.youtube.com/watch?v=yHrQ1uaA44g>

02/22

Presentation ceremony of the Health and Climate Change Observatory

<https://www.youtube.com/watch?v=Kj3S3OLq18w&t=160s>



March

03/05

Commemoration of International Women's Day. Women's relationship with the health system

https://www.youtube.com/watch?v=J4UaZWXL_64



April

04/03

III Conference of the National Epidemiology Centre: Get to know the CNE

<https://www.youtube.com/watch?v=EF63MudGbB8&t=11843s>

04/19

Visit to the Majadahonda Campus of the ISCIII by the FioCruz Foundation of Brazil

<https://www.youtube.com/watch?v=BYh97-ANOJg>

04/03

This is how the CNE works. Informative video on the work of the National Centre for Epidemiology

<https://www.youtube.com/watch?v=1OXhjnK0tXE&t=8s>

04/22

Science between the lines. Jordi Cano: 'Mind-blowing journey'

https://www.youtube.com/watch?v=e_MPTaU9H_g&t=58

04/04

ISCIII Doping Control Laboratory. General description of activity and functions

<https://www.youtube.com/watch?v=1Ovfunu2wgM&t=25s>

Science between the lines. Marta Soler: 'Microbiota: the microbes in your body'

<https://www.youtube.com/watch?v=3pitaAmgEJY&t=29s>

Science between the lines. Ignacio Pérez de Castro: 'My life in science'

<https://www.youtube.com/watch?v=cVLMlhvfRI&t=69s>

Science between the lines. Cristina Linares: 'Silent Spring'

<https://www.youtube.com/watch?v=6dQtvXVLJgl&t=16s>

04/25

Cuidamos+75 Conference

<https://www.youtube.com/watch?v=wshbTQPMWE8>

04/26

Immunology Day at the ISCIII

<https://www.youtube.com/watch?v=OfOwr14-vhc>

May

05/07

RICH Europe 1st Symposia. "The role of the RIs in the Open Science and the ERA implementation"

<https://www.youtube.com/watch?v=CDeW4XWMYDU>

<https://www.youtube.com/watch?v=B1AAFQTdEpU>

<https://www.youtube.com/watch?v=lx-MCnTI73c>


<https://www.youtube.com/watch?v=8DIDJqZ6s2k>

05/08 to 05/09

Presentation of the Instructions for the implementation and justification of ESA Grants

<https://www.youtube.com/watch?v=P8oqi2XhpEA>

<https://www.youtube.com/watch?v=Wc75yAcPc9o&t=10s>



June

06/18

ISCIII scientific dissemination activities for the Open Government Week 2024

<https://www.youtube.com/watch?v=eZHH5rdpU-Q>

06/19

Day: European Research Infrastructures in the Health Area

<https://www.youtube.com/watch?v=yLBccOKgrmg&t=14947s>

06/27

Call ISCIII RRI in Health 2024_Proposals presented

<https://www.youtube.com/watch?v=IScXgVA7ENc&t=297s>

July

07/04

Presentation of ISCIII calls for R&D&I in Health

https://www.youtube.com/watch?v=sgoKRTe_jeo&t=1299s

07/09

Launch of the website "Behaviour in Health"

<https://www.youtube.com/watch?v=Rsf34DIUdYo&t=397s>

07/16

Visit to the ISCIII of a delegation from the University of South Carolina in the United States

<https://www.youtube.com/watch?v=sEIT6JR96Bo>

September

09/25

Day: Epidemiological, clinical and microbiological impact of the Mpox outbreak in Spain

<https://www.youtube.com/watch?v=hkioLos3Cg8&t=7360s>

09/27

The European Researchers' Night

"Scientific circuit: Research to improve health"

<https://www.youtube.com/watch?v=vfLJpkx4iaU&t=9s>

October

10/03

VI Research Coordination Day on Care Research in Thematic Research Structures

<https://www.youtube.com/watch?v=f-dQbb8jrrU&t=10275s>

10/09

Visit to the ISCIII by the SG for Research of the Ministry of Science, Innovation and Universities

<https://www.youtube.com/watch?v=8PxSVuBBC5g&t=13s>

November

11/05 to 11/17

Science and Innovation Week

<https://www.youtube.com/watch?v=pUjqz85q8Dc&t=3s>

11/18

IMPACT Day

<https://www.youtube.com/watch?v=HPryWmXpB7o>

11/27

Conference on Equality at the Carlos III Health Institute

<https://www.youtube.com/watch?v=rHHb46Y9M5k&t=3924s>

11/07

The 2024 Good Practice in Responsible Research and Innovation Awards

<https://www.youtube.com/watch?v=1OTZa9iA-fQ>

11/18

Jesús Oteo CNM antibiotic resistance 2024

<https://www.youtube.com/watch?v=OUdp6VVRQno>

December

12/12

Conference for the Centenary of the National Health School (ENS) of the ISCIII

<https://www.youtube.com/watch?v=wxg2Tgl5Vp4&t=5s>

<https://www.youtube.com/watch?v=QRlqk9vW1gM&t=7s>

<https://www.youtube.com/watch?v=h8K6hgyMlj4&t=27s>

<https://www.youtube.com/watch?v=4xwDdDC1mMo>

12/16

Info Day Informative online session for EffectTrial applicants

<https://www.youtube.com/watch?v=QjXNaOI02tM&t=532s>

12/17

I Dendrite Day: Innovation in Cognitive Impairment

<https://www.youtube.com/watch?v=HvTJctR8OEw>

12/19

Information Session on 2025 European Calls

<https://www.youtube.com/watch?v=SQyzlhV6PIA>

12/31

Summary ISCIII 2024: 10 years of the CIBER Consortium

<https://www.youtube.com/watch?v=XBP5dCN8S8w>



isc
Instituto
de Salud
Carlos III

ens.

100

**Centenario Escuela
Nacional de Sanidad
1924 - 2024**



